Abstracts tagged "Scleroderma"

Abstract Number: 1622 • ACR Convergence 2022
TNF Receptor 1 Drives Murine Pulmonary Arterial Hypertension and Is Characterized by Loss of Capillary Endothelial Cells and Pericytes, Smooth Muscle Cell Proliferation, and Alterations in Fibroblast Phenotype
Stacey Duemmel¹, Marc Nuzzo¹, Soumyaroop Bhattacharya¹, Qingfu Xu¹, Amy Mohan¹ and Benjamin Korman², ¹URMC, Rochester, NY, ²University of Rochester, Rochester, NY
Background/Purpose: We previously demonstrated that TNF-transgenic (TNF-Tg) mice have findings consistent with connective-tissue disease associated pulmonary arterial hypertension (CTD-PAH), and that this pathology is mediated…
Abstract Number: 2171 • ACR Convergence 2022
Serum IFN Score Predicts Long Term Outcome in Limited Cutaneous Systemic Sclerosis
Ranjitha Karanth¹, Giuseppina Abignano², Vishal Kakkar¹, Rebecca Ross¹, Chris Denton³ and Francesco Del Galdo⁴, ¹University of Leeds, Leeds, United Kingdom, ²Istituto Reumatologico Lucano (IReL), Azienda Ospedaliera Regionale San Carlo, Potenza, Italy, ³University College London, London, United Kingdom, ⁴Leeds Institute of Rheumatic and Musculoskeletal Medicine, Faculty of Medicine and Health and NIHR Biomedical Research Centre, University of Leeds, Leeds, United Kingdom
Background/Purpose: Type-I Interferon pathway activation has been associated with severity and progression of diffuse cutaneous SSc (dcSSc). The role of type-I Interferons (IFNs) in limited…
Abstract Number: 1054 • ACR Convergence 2022
Distinct Differences in Complement Perturbation Between Scleroderma-related Interstitial Lung Disease with and Without Emphysema
Claire Beesley¹, Alice Cole², Nina Goldman¹, Odewale Oluwakorede¹, Joseph Barnett², David Abraham¹, Chris Denton¹, Rizgar Mageed³ and Voon Ong⁴, ¹University College London, London, United Kingdom, ²Royal Free Hospital, London, United Kingdom, ³Experimental Medicine and Rheumatology, William Harvey Research Institute, Queen Mary University, London, United Kingdom, ⁴UCL Medical School Royal Free Campus, London, United Kingdom
Background/Purpose: Aberrant complement activation is associated with autoimmune diseases including systemic sclerosis (SSc). As a leading cause of death in SSc, interstitial lung disease (ILD)…
Abstract Number: 1183 • ACR Convergence 2022
Functionally Distinct Fibroblast Populations in Systemic Sclerosis Skin Revealed by Explant Tissue Characterization and Single-cell RNAseq
Kristina Clark¹, Alice Cole², Shiwen Xu¹, Voon Ong³, Christopher Buckley⁴ and Chris Denton¹, ¹University College London, London, United Kingdom, ²Royal Free Hospital, London, United Kingdom, ³UCL Medical School Royal Free Campus, London, United Kingdom, ⁴University of Oxford, Oxford, United Kingdom
Background/Purpose: Traditional studies of skin fibroblasts in SSc focus on the early "migratory" fibroblast population derived from explant culture of skin biopsies. Single-cell RNAseq has…
Abstract Number: 1657 • ACR Convergence 2022
Extreme Phenotype Approach Identifies Rare Variants in Systemic Sclerosis and Dermatomyositis Patients with Severe Calcinosis
Srijana Davuluri¹, Urvashi Kaundal², Christian Lood³, Puneet Kapoor¹, Yumeko Kawano⁴, Stefania Dell'Orso⁵, Zuoming Deng⁶, Zsuzsanna McMahan⁷, Ami Shah⁷, Laura Hummers⁸, Daniel Kastner⁹, Fredrick Wigley¹⁰, David Fiorentino¹¹, Pravitt Gourh¹² and Lorinda Chung¹¹, ¹Stanford University School of Medicine, Palo Alto, CA, ²National Institutes of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), National Institutes of Health (NIH), Bethesda, MD, ³Division of Rheumatology, University of Washington, Seattle, WA, ⁴Brigham and Women's Hospital, Boston, MA, ⁵NIH, Bethesda, MD, ⁶National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, MD, ⁷Johns Hopkins Rheumatology, Baltimore, MD, ⁸Johns Hopkins Univerisity, Baltimore, MD, ⁹National Human Genome Research Institute, Bethesda, MD, ¹⁰Johns Hopkins University, Baltimore, MD, ¹¹Stanford University, Stanford, CA, ¹²National Institutes of Health, Bethesda, MD
Background/Purpose: Calcinosis, deposition of insoluble calcium salts in skin and subcutaneous tissues, affects up to 40% of systemic sclerosis (SSc) patients, and up to 20%…
Abstract Number: 2173 • ACR Convergence 2022
Rheumatology Telemedicine Consults: Impact of Demographic Variability on Patient Perception in Systemic Sclerosis versus Rheumatoid Arthritis Pts
Yossra Suliman¹, Julia mumper², Gary Feldman³, M. Cameron Hay⁴ and Daniel Furst⁵, ¹Assiut University Hospital, Assiut, Egypt, ²Miami University, Miami, OH, ³Pacific Arthritis, Los Angeles, CA, ⁴Miami University (Ohio), Oxford, OH, ⁵University of California Los Angeles, Los Angeles, CA
Background/Purpose: In the era of emerging need to utilize remote technology-based health care services due to the COVID-19 pandemic, we wanted to evaluate patient satisfaction…
Abstract Number: 1055 • ACR Convergence 2022
Associations of Potential Risk Factors with Severe Outcomes in Scleroderma Renal Crisis: Results from a Single Center Study
Alex Luta¹, Saloni Godbole¹ and Virginia Steen², ¹Medstar Georgetown University Hospital, Washington, DC, ²Georgetown University School of Medicine, Washington, DC
Background/Purpose: Scleroderma Renal Crisis (SRC) is a severe and life-threatening complication of Systemic Sclerosis (SSc). Given the rare nature of SSc, it is challenging to…
Abstract Number: 1184 • ACR Convergence 2022
Intracellular Calcium Signals Regulate the Pro-fibrotic Phenotype of Scleroderma Fibroblasts via Calcium/calmodulin-dependent Kinase II
Sirapa Vichaikul¹, William Brodie², Megan Mattichak², Qi Wu², Dinesh Khanna² and Eliza Pei-Suen Tsou², ¹Michigan Medicine, Howell, MI, ²University of Michigan, Ann Arbor, MI
Background/Purpose: We performed an in-depth analysis of the involvement of histone reader bromodomain extra-terminal proteins (BETs) in scleroderma (SSc) fibrosis and showed that JQ1, a…
Abstract Number: 1658 • ACR Convergence 2022
Association Between Anti-Sjögren Syndrome/Scleroderma Autoantigen 1 (SSSCA1) Antibodies and Cancer in Systemic Sclerosis
Rachel Wallwork¹, Livia Casciola-Rosen¹ and Ami Shah², ¹Johns Hopkins University, Baltimore, MD, ²Johns Hopkins Rheumatology, Baltimore, MD
Background/Purpose: We sought to examine the association between anti-Sjögren syndrome/scleroderma autoantigen 1 (SSSCA1) antibody and cancer in systemic sclerosis (SSc). We also describe the frequency…
Abstract Number: 2174 • ACR Convergence 2022
Influence of Immunosuppressive Therapy on Gastrointestinal Symptoms in Patients with Systemic Sclerosis
Lea Stamm¹, Alexandru Garaiman¹, Norina Zampatti¹, Mike Becker¹, Cosimo Bruni¹, Rucsandra Dobrota¹, Muriel Elhai¹, Sherif Ismail², Suzana Jordan¹, Aurora Tatu³, Oliver Distler¹ and Carina Mihai¹, ¹Department of Rheumatology, University Hospital Zurich, University of Zurich, Zürich, Switzerland, ²Department of Internal Medicine, National Research Center, Cairo, Egypt, ³Department of Gastroenterology, University Hospital Zurich, University of Zurich, Zürich, Switzerland
Background/Purpose: The gastrointestinal (GI) tract is frequently affected in systemic sclerosis (SSc), leading to considerable morbidity and even mortality. While important progress has been made…
Abstract Number: 1056 • ACR Convergence 2022
Clinical Characterization of a Cohort of Patient with Sclerotic-type Chronic Graft-versus-host Disease with Fascial/joint Involvement
Cristina Hidalgo¹, Concepción Roman², Olga Compan³, Sonia Pastor Navarro⁴, Marta Ibañez⁵, Belen Miguel⁶, Maria Dolores Sanchez⁷, Lucía Pantoja⁸, Carlos Montilla⁵ and Lucía López-Corral², ¹Hospital Universitario Salamanca, Salamanca, Spain, ²Universitary Hospital, Salamanca, Spain, ³Complejo asistencial Universitario de Palencia, Carbajosa De La Sagrada, Spain, ⁴Hospital Universitario de Salamanca, Salamanca, Spain, ⁵Complejo asistencial Universitario de Salamanca, Salamanca, Spain, ⁶University Hospital, Salamanca, Spain, ⁷Universitary Hospital, Valladolid, Spain, ⁸Complejo Asistencial Hospital General, Segovia, Spain
Background/Purpose: Graft-versus-host disease (GVHD) is the most frequent complication after allogeneic hematopoietic cell transplantation (allo-HCT). Its chronic form usually involves a multisystemic syndrome that reflects…
Abstract Number: 1190 • ACR Convergence 2022
Multimorbidity in Systemic Sclerosis: Burden and Trends in Prevalence from an Incident Population-based Cohort (1980-2018)
Ashima Makol¹, Sara Achenbach¹, Alicia Hinze², Tina Gunderson³ and Cynthia Crowson⁴, ¹Mayo Clinic, Rochester, MN, Rochester, MN, ²Mayo Clinic - Rochester, MN, Rochester, MN, ³Mayo Clinic, Rochester, MN, ⁴Mayo Clinic, Eyota, MN
Background/Purpose: To estimate the prevalence and trends of multimorbidity (MM; the presence of ≥2 morbidities) in a population-based cohort of patients with Systemic sclerosis (SSc)…
Abstract Number: 1662 • ACR Convergence 2022
Nationwide Distribution of Other Connective Tissue Disease (OCTD) and Systemic Sclerosis (SSc) in Areas of Environmental Concern
Noelle Kosarek¹, Megan Romano², Robert Simms³, Angeline Andrew⁴, Erika Moen⁴, Patricia pioli⁴ and Michael Whitfield⁵, ¹Dartmouth Geisel School of Medicine, Lebanon, NH, ²Dartmouth College, Lebanon, NH, ³Dartmouth Hitchcock Medical Center, Lebanon, NH, ⁴Geisel School of Medicine at Dartmouth, Lebanon, NH, ⁵Dartmouth Geisel School of Medicine, Department of Biomedical Data Science, Lebanon, NH
Background/Purpose: Systemic sclerosis (SSc) is a rare autoimmune disease characterized by fibrosis of the skin and internal organs, vascular abnormalities, and autoantibody formation. The etiology…
Abstract Number: 2190 • ACR Convergence 2022
Characterizing Compensatory Cognitive Strategy Use in People with Systemic Sclerosis
Yen Chen¹, Alain Lescoat², Dinesh Khanna³ and Susan Murphy⁴, ¹University of Michigan, Ann Arbor, MI, ²CHU Rennes - University Rennes 1, Rennes, France, ³Division of Rheumatology, Department of Internal Medicine, Scleroderma Program, University of Michigan, Ann Arbor, MI, ⁴University of Michigan, Grosse Ile, MI
Background/Purpose: Individuals with systemic sclerosis (SSc) report cognitive problems that worsen symptoms and daily activity performance. Compensatory cognitive strategies (CCS) are commonly taught to help…
Abstract Number: 1090 • ACR Convergence 2021
Contribution of Scleroderma/Myositis-Related Antibodies Detected by Immunoblot to the Diagnosis of Systemic Autoimmune Rheumatic Diseases in 134 Patients from a Single Referral Center
Diana Prieto-Peña¹, Belén Atienza-Mateo², Miguel Ángel gonzalez-Gay³, Ricardo Blanco⁴ and Marcos Lopez-Hoyos⁵, ¹Hospital Universitario Marqués de Valdecilla, santander, Spain, ²Group "Research in genetic epidemiology and atherosclerosis of systemic diseases and in bone metabolic diseases of the locomotor system", IDIVAL; and Department of Rheumatology, Hospital Universitario Marqués de Valdecilla, Santander, Spain, ³Research group on Genetic Epidemiology and Atherosclerosis in Systemic Diseases and in Metabolic Bone Diseases of the Musculoskeletal System, IDIVAL, Division of Rheumatology, Hospital Universitario Marqués de Valdecilla; School of Medicine, Universidad de Cantabria, Santander, Spain. Cardiovascular Pathophysiology and Genomics Research Unit, School of Physiology, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa, ⁴Hospital Universitario Marqués de Valdecilla, IDIVAL, Santander, Spain, ⁵Marques de Valdecilla University Hospital-IDIVAL, Santander, Spain
Background/Purpose: Immunoblot assays are increasingly used in clinical practice as part of the diagnostic armamentarium of systemic autoimmune rheumatic diseases (SARDs). Our aim was to…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].